Is Delayed Weightbearing After Matrix-Associated Autologous Chondrocyte Implantation in the Knee Associated With Better Outcomes?

A Systematic Review of Randomized Controlled Trials

Matthew J. Kraeutler,*† MD, John W. Belk‡, Trevor J. Carver‡ BA, and Eric C. McCarty‡ MD

Investigation performed at CU Sports Medicine and Performance Center, Department of Orthopedics, University of Colorado School of Medicine, Boulder, Colorado, USA

Background: Proper rehabilitation after matrix-associated autologous chondrocyte implantation (MACI) is essential to restore a patient’s normal function without overloading the repair site.

Purpose: To evaluate the current literature to assess clinical outcomes of MACI in the knee based on postoperative rehabilitation protocols, namely, the time to return to full weightbearing (WB).

Study Design: Systematic review; Level of evidence, 1.

Methods: A systematic review was performed to locate studies of level 1 evidence comparing the outcomes of patients who underwent MACI with a 6-week, 8-week, or 10/11-week time period to return to full WB. Patient-reported outcomes assessed included the Knee injury and Osteoarthritis Outcome Score (KOOS), Tegner activity scale, Short Form Health Survey–36 (SF-36), and visual analog scale (VAS) for pain frequency and severity.

Results: Seven studies met the inclusion criteria, including a total of 136 patients (138 lesions) who underwent MACI. Treatment failure had occurred in 0.0% of patients in the 6-week group, 7.5% in the 8-week group, and 8.3% in the 10/11-week group at a mean follow-up of 2.5 years (P = .46). KOOS, SF-36, and VAS scores in each group improved significantly from preoperatively to follow-up (P < .001).

Conclusion: Patients undergoing MACI in the knee can be expected to experience improvement in clinical outcomes with the rehabilitation protocols outlined in this work. No significant differences were seen in failure rates based on the time to return to full WB.

Keywords: autologous chondrocyte implantation; rehabilitation; articular cartilage

Articular cartilage injuries in the knee joint are common, with a prevalence of 32% in patients in their 20s undergoing knee arthroscopic surgery and 46% of patients in their 30s.5,7 Articular cartilage has a limited capacity for spontaneous repair after an injury,3 and if left untreated, full-thickness cartilage lesions can lead to symptoms such as pain, swelling, and joint dysfunction.4 Several operative methods exist to treat these lesions,25,30 although autologous chondrocyte implantation (ACI) has gained significant interest recently, with several clinical trials currently being conducted in the United States.23

Third-generation ACI, or matrix-associated ACI (MACI), is performed in a 2-step process in which a patient undergoes knee arthroscopic surgery to obtain a biopsy of healthy cartilage. Chondrocytes from this biopsy sample are then
cultured over several weeks and implanted into a collagen or hyaluronan-based scaffold before being cut to the shape and size of the patient’s chondral defect and fixed to the defect with fibrin glue. Favorable midterm to long-term outcomes have been demonstrated after MACI in the knee joint, with a 9.4% failure rate at a minimum 5-year follow-up.31

A recent review showed that 13 of 22 studies of MACI in the knee joint either did not report or did not adequately describe their postoperative rehabilitation protocol.2 Proper rehabilitation after MACI is essential to restore a patient’s normal function without overloading the repair site.13 Thus, it is important to establish an effective rehabilitation protocol for health care providers and patients undergoing this procedure. The purpose of this systematic review was to evaluate the current literature to assess the clinical outcomes of MACI based on postoperative rehabilitation protocols, in particular the time to return to full weightbearing (WB). We hypothesized that no significant differences in clinical outcomes would be found based on the rehabilitation protocol.

METHODS

A systematic review of multiple databases was performed. Two independent reviewers searched PubMed, Embase, and Cochrane Library up to February 9, 2017, using the search phrase “autologous chondrocyte knee rehabilitation.” A total of 339 studies were reviewed by title and/or abstract to determine study relevance based on inclusion/exclusion criteria. Inclusion criteria consisted of studies with level 1 evidence and a minimum 12-month follow-up in which clinical outcomes were compared between at least 2 groups of patients with different times until return to full WB. Studies were excluded if postoperative assessments were not used, if they were nonclinical or noncomparative studies, or if they were unrelated to the knee. Seven studies met inclusion and exclusion criteria (Figure 1).

TABLE 1
Matrix-Associated Autologous Chondrocyte Implantation Products

| Study          | Matrix Scaffold                | Manufacturer                |
|----------------|-------------------------------|----------------------------|
| Ebert et al8 (2017) | Type I/III collagen membrane | Matricel                    |
| Ebert et al9 (2011) | (ACI-Maix)                    |                            |
| Ebert et al10 (2012) |                               |                            |
| Ebert et al11 (2010) |                               |                            |
| Edwards et al12 (2013) | Type I collagen membrane or | Arthro Kinetics;            |
|                  | Hyalograft C                   | Fidia Advanced Biopolymers |

TABLE 2
Rehabilitation Protocols

| Study          | 6 wk | 8 wk | 10/11 wk |
|----------------|------|------|----------|
| Ebert et al8 (2017) | X    | X    |          |
| Ebert et al9 (2011) | X    | X    | X        |
| Ebert et al10 (2012) | X    | X    | X        |
| Ebert et al11 (2010) | X    | X    | X        |
| Edwards et al12 (2013) | X    | X    |          |
| Wondrasch et al15 (2009) | X    | X    |          |
| Wondrasch et al16 (2015) | X    | X    |          |

Each study randomized patients into 2 of the following 3 rehabilitation protocols: 6-week, 8-week, or 10/11-week return to full weightbearing.

Surgical Technique

Each study8-12,35,36 used a third-generation MACI product. This procedure is a 2-stage technique in which an arthroscopic approach is first used to harvest a sample of normal articular cartilage from a non-WB region of the knee. Chondrocytes are then isolated, cultured, and seeded onto a collagen or hyaluronan-based scaffold. At 3 to 8 weeks after the chondral biopsy, the second stage of the procedure involves mini-arthrotomy to implant the scaffold in the lesion site. The chondral defect is prepared by removing all damaged cartilage down to the subchondral plate and is then used to shape the scaffold, which is pressed into the lesion site and secured with a thin layer of fibrin glue. The graft is assessed for stability before the wound is closed. Two studies8,12 performed the second stage of the MACI procedure either arthroscopically or through mini-arthrotomy. In addition to the 2 different MACI techniques, there was also a variety of matrix scaffold types and manufacturers used (Table 1). Two studies35,36 did not use the same matrix in all patients.

Rehabilitation Protocols

Patients in all included studies were randomized into either a 6-week, 8-week, or 10/11-week time period before return to full WB (Table 2). Four studies8,12,35,36 described a 6-week rehabilitation protocol consisting of an initial
2-week period of WB at 20%, followed by a progressive increase to full WB at 6 weeks postoperatively. Five studies\textsuperscript{8-12} described an 8-week rehabilitation protocol consisting of a 2-week period of WB at 20%, with a progressive increase to full WB at 8 weeks postoperatively. Two studies\textsuperscript{35,36} described a 10-week rehabilitation protocol consisting of toe-touch WB for 4 weeks, followed by partial WB at 20% between weeks 4 and 6, 50% WB between weeks 6 and 8, and full WB by 10 weeks postoperatively. Three studies\textsuperscript{8-11} described an 11-week rehabilitation protocol consisting of a 5-week period of WB at 20%, with a progressive increase to full WB at 11 weeks. All 7 studies used continuous passive motion (CPM) as part of the rehabilitation process for all patients included. Five studies\textsuperscript{8-12} began CPM within 12 to 24 hours after surgery from 0° to 30° of flexion, and 2 studies\textsuperscript{35,36} used CPM for 3 hours per day beginning 24 hours postoperatively from 0° to 40° of flexion.

Outcomes

Outcome measures included patient-reported outcome scores, magnetic resonance imaging (MRI) findings, functional test results, and treatment failure. The Knee injury and Osteoarthritis Outcome Score (KOOS)\textsuperscript{28} was used in 6 studies.\textsuperscript{8-11,35,36} Two studies\textsuperscript{35,36} used the Tegner activity scale.\textsuperscript{32} Four studies\textsuperscript{8-11} used the Short Form Health Survey–36 (SF-36)\textsuperscript{34} and the visual analog scale (VAS) for pain frequency and severity. All studies used high-resolution MRI to assess graft adherence postoperatively. Four studies\textsuperscript{8-11} used the MRI composite score, 2 studies\textsuperscript{35,36} used the MOCART (magnetic resonance observation of cartilage repair tissue) scoring system,\textsuperscript{24} and 1 study\textsuperscript{11} did not describe any MRI results beyond stating that there was no complete graft delamination in any patient as assessed by MRI. The 6-minute walk test,\textsuperscript{16} a test to assess the maximum distance that each patient could comfortably walk in a 6-minute time period, and active knee flexion and extension were the most common functional tests used to assess patients postoperatively. Four studies\textsuperscript{8-11} reported 6-minute walk test results and measured active knee flexion and extension.

Methodology Assessment

The Modified Coleman Methodology Score (MCMS)\textsuperscript{6} was used to evaluate study methodology quality. The MCMS has a scaled potential score ranging from 0 to 100. Scores of 85-100 are excellent, 70-84 are good, 55-69 are fair, and <55 are poor.

Treatment Failure

Five of the 7 studies reported treatment failure. Four studies\textsuperscript{8,10-12} defined treatment failure as complete delamination of the implanted graft and its resulting inability to withstand dynamic forces placed upon it during return to full WB, while 1 study\textsuperscript{8} defined treatment failure as a subchondral bed devoid of any significant repair tissue. Two studies\textsuperscript{35,36} did not report on treatment failure. Only the latest follow-up was used from each population sample group to assess treatment failure.

Statistical Analysis

A chi-square test was used to compare lesion locations and treatment failure rates between groups. For patient-reported outcomes, a weighted mean ± composite SD was calculated for each group, as previously described.\textsuperscript{22} Preoperative and postoperative scores were compared within each group using a 2-samples independent t test based on unequal variance (http://www.openepi.com).

RESULTS

The 7 studies included in the review had overlapping patients. Overall, there were a total of 3 separate patient samples, including 136 nonoverlapping patients and 138 nonoverlapping lesions.

Patient Demographics

Patient demographics are shown in Table 3. There were a total of 34 lesions treated with the 6-week protocol, 53 lesions treated with the 8-week protocol, and 51 lesions treated with the 10/11-week protocol. A total of 37 lesions were treated on the lateral femoral condyle and 101 on the medial femoral condyle. No significant difference was found between groups with regard to lesion location (\(P = .85\)). Although all patients were randomized to the different rehabilitation protocols, a trend was noted, with younger patients being randomized to the shorter duration protocols. Three studies\textsuperscript{8,12,35} directly compared body mass index between study groups and found no significant differences.

Modified Coleman Methodology Score

Table 4 shows the MCMS scores from the 7 included studies. One study\textsuperscript{10} achieved an excellent score, 4 studies achieved good scores, and 2 studies achieved fair scores.

Treatment Failure

Overall, 6.5% of patients experienced graft failure (6 wk: 0.0%; 8 wk: 7.5%; 10/11 wk: 8.3%; \(P = .46\)) at a mean follow-up of 2.5 years (Table 5). Ebert et al\textsuperscript{10} found that 5 patients experienced graft failure, including 2 patients at 2-year follow-up (8 wk: \(n = 1\); 10/11 wk: \(n = 1\)) and 3 more at 5-year follow-up (8 wk: \(n = 1\); 10/11 wk: \(n = 2\)). In addition to treatment failure, Ebert et al\textsuperscript{10} reported that seven 8-week patients and six 10/11-week patients experienced graft hypertrophy as detected by MRI at 5-year follow-up. Studies did not report on the age or sex of the patients who failed treatment.

MRI Assessment

Two studies of overlapping patients\textsuperscript{9,10} reported significant improvement (\(P < .0001\)) in the MRI composite score among
the 8-week and 10/11-week rehabilitation groups from 3 months to 24 months postoperatively and then again from 24 months to 5 years ($P < .05$). However, there was no significant difference in improvement between the 2 groups at either time interval. Another study found that 100% of patients in the 6-week group had MRI composite scores that were graded as good to excellent, compared with 78% in the 8-week group. Both groups experienced significant improvement ($P < .0001$) in the MRI composite score from 3 months to 24 months postoperatively, with no significant difference in improvement between groups. Edwards et al. found that 100% of patients in the 6-week group demonstrated good to excellent MRI composite scores, compared with 85% in the 8-week group. Both groups improved significantly ($P < .001$) from 12 weeks to 12 months postoperatively, with no significant difference in improvement between groups. Two studies of overlapping patients reported that the 6-week and 10/11-week groups demonstrated significant improvements ($P < .05$) in the MOCART score from 4 weeks to 2 years postoperatively. However, from 2- to 5-year follow-up, both groups experienced significant decreases ($P < .05$) in the MOCART score. There was a significantly higher MOCART score in the 10/11-week group (67.2 points) compared with the 6-week group (59.7 points) at 4 weeks postoperatively.

### TABLE 3
Patient Demographics

| Study                        | No. of Lesions | Lesion Size, cm² | Age at Surgery, y | Weight, kg | Height, m | BMI, kg/m² | Lesion Location, n |
|------------------------------|----------------|------------------|-------------------|------------|-----------|------------|-------------------|
| 6 wk                         |                |                  |                   |            |           |            |                   |
| Ebert et al (2017)           | 18             | 3.2              | 36.4              | 82.3       | 1.76      | 26.2       | LFC: 5, MFC: 13    |
| Edwards et al (2013)         |                |                  |                   |            |           |            |                   |
| Wondrasch et al (2015)       | 16             | 5.1              | 28.3              | NR         | NR        | 24.7       | LFC: 4, MFC: 12    |
| Wondrasch et al (2009)       |                |                  |                   |            |           |            |                   |
| Total                        | 34             | 4.1              | 32.6              | 82.3       | 1.76      | 25.5       | LFC: 9, MFC: 25    |
| 8 wk                         |                |                  |                   |            |           |            |                   |
| Ebert et al (2017)           | 19             | 2.9              | 36.4              | 79.4       | 1.77      | 25.2       | LFC: 5, MFC: 14    |
| Edwards et al (2013)         |                |                  |                   |            |           |            |                   |
| Ebert et al (2011)           | 34             | 3.2 ± 0.5        | 36.6 ± 1.9        | 79.0 ± 1.8 | 1.74 ± 0.02 | 25.6       | LFC: 8, MFC: 26    |
| Ebert et al (2012)           |                |                  |                   |            |           |            |                   |
| Ebert et al (2010)           |                |                  |                   |            |           |            |                   |
| Total                        | 53             | 3.1              | 36.5              | 79.1       | 1.75      | 25.5       | LFC: 13, MFC: 40   |
| 10/11 wk                     |                |                  |                   |            |           |            |                   |
| Ebert et al (2011)           | 36             | 3.3 ± 0.5        | 39.7 ± 2.3        | 83.8 ± 2.4 | 1.74 ± 0.2 | 27.6       | LFC: 10, MFC: 26   |
| Ebert et al (2012)           |                |                  |                   |            |           |            |                   |
| Ebert et al (2010)           |                |                  |                   |            |           |            |                   |
| Wondrasch et al (2015)       | 15             | 4.6              | 38.0              | NR         | NR        | 24.8       | LFC: 5, MFC: 15    |
| Wondrasch et al (2009)       |                |                  |                   |            |           |            |                   |
| Total                        | 51             | 3.7              | 39.2              | 83.8       | 1.74      | 26.8       | LFC: 15, MFC: 36   |

*Lesion size, age, weight, height, and BMI are all reported as mean ± SD (if available), with “total” reported as weighted mean. Only the nonoverlapping patient samples are included to avoid redundancy. BMI, body mass index; LFC, lateral femoral condyle; MFC, medial femoral condyle; NR, not reported.

### TABLE 4
Modified Coleman Methodology Score

| Study                        | Mean Score |
|------------------------------|------------|
| Ebert et al (2017)           | 68         |
| Ebert et al (2011)           | 84         |
| Ebert et al (2012)           | 87         |
| Ebert et al (2013)           | 84         |
| Edwards et al (2013)         | 68         |
| Wondrasch et al (2015)       | 81         |
| Wondrasch et al (2009)       | 78         |
| Total                        | 78.6 ± 7.7 |

### TABLE 5
Treatment Failure

| Study                        | 6 wk | 8 wk | 10/11 wk | Total |
|------------------------------|------|------|----------|-------|
| Ebert et al (2017)           | 0/18 (0.0) | 2/19 (10.5) | —  | 2/37 (5.4) |
| Edwards et al (2013)         |      |      |          |       |
| Ebert et al (2011)           |      | 2/34 (5.9) | 3/36 (8.3) | 5/70 (7.1) |
| Ebert et al (2012)           |      |      |          |       |
| Ebert et al (2010)           |      |      |          |       |
| Wondrasch et al (2015)       |      |      |          |       |
| Wondrasch et al (2009)       |      |      |          |       |
| Total                        | 0/18 (0.0) | 4/53 (7.5) | 3/36 (8.3) | 7/107 (6.5) |

*Failures are reported as number of failures/total number of lesions (%). Only the 3 nonoverlapping patient samples are included to avoid redundancy. NR, not reported.
Improvement was noted from preoperatively to latest SF-36 and VAS regression was found between groups. Otherwise, no significant difference in improvement or ().

The Orthopaedic Journal of Sports Medicine Weightbearing After MACI

| Study                        | Preoperative | Postoperative | Preoperative | Postoperative | Preoperative | Postoperative |
|------------------------------|--------------|---------------|--------------|---------------|--------------|---------------|
| VAS (frequency)              |              |               |              |               |              |               |
| Ebert et al<sup>10</sup> (2017) | 6.3 ± 0.6    | 1.6 ± 0.5     | 6.5 ± 0.7    | 1.4 ± 0.5     | —            | —             |
| Ebert et al<sup>10</sup> (2011) | —            | —             | 4.8 ± 0.5    | 2.2 ± 0.5     | 5.4 ± 0.5    | 2.9 ± 0.5     |
| Ebert et al<sup>13</sup> (2010) | —            | —             | (n = 34)     | (n = 34)      | (n = 36)     | (n = 36)      |
| Ebert et al<sup>10</sup> (2012) | —            | —             | (n = 31)     | (n = 31)      | (n = 32)     | (n = 32)      |
| Total                        | 6.3 ± 0.6    | 1.6 ± 0.5     | 5.2 ± 0.9    | 2.0 ± 0.6     | 5.4 ± 0.5    | 3.1 ± 0.5     |
| Mean improvement             | −4.7         | −3.2          | −4.7         | −3.2          | −3.2         | −3.2          |
| Mean follow-up, y            | 2.0          | 3.1           | 2.0          | 3.1           | 3.6          | 3.6           |

| Study                        | Preoperative | Postoperative | Preoperative | Postoperative | Preoperative | Postoperative |
|------------------------------|--------------|---------------|--------------|---------------|--------------|---------------|
| VAS (severity)               |              |               |              |               |              |               |
| Ebert et al<sup>10</sup> (2017) | 5.7 ± 0.6    | 1.7 ± 0.4     | 5.3 ± 0.6    | 1.8 ± 0.4     | —            | —             |
| Ebert et al<sup>13</sup> (2013) | (n = 18)     | (n = 18)      | (n = 19)     | (n = 19)      | —            | —             |
| Ebert et al<sup>10</sup> (2011) | —            | —             | 4.6 ± 0.5    | 2.0 ± 0.3     | 4.4 ± 0.5    | 2.5 ± 0.3     |
| Ebert et al<sup>13</sup> (2010) | —            | —             | (n = 34)     | (n = 34)      | (n = 36)     | (n = 36)      |
| Ebert et al<sup>10</sup> (2012) | —            | —             | (n = 31)     | (n = 31)      | (n = 32)     | (n = 32)      |
| Total                        | 5.7 ± 0.6    | 1.7 ± 0.4     | 4.8 ± 0.6    | 2.0 ± 0.4     | 4.4 ± 0.5    | 2.4 ± 0.3     |
| Mean improvement             | −4.0         | −2.8          | −4.0         | −2.8          | −2.0         | −2.0          |
| Mean follow-up, y            | 2.0          | 3.1           | 2.0          | 3.1           | 3.6          | 3.6           |

| Study                        | Preoperative | Postoperative | Preoperative | Postoperative | Preoperative | Postoperative |
|------------------------------|--------------|---------------|--------------|---------------|--------------|---------------|
| SF-36 PCS                    |              |               |              |               |              |               |
| Ebert et al<sup>10</sup> (2017) | 35.1 ± 1.9   | 49.1 ± 2.5    | 39.6 ± 2.1   | 50.2 ± 2.7    | —            | —             |
| Ebert et al<sup>13</sup> (2013) | (n = 18)     | (n = 18)      | (n = 19)     | (n = 19)      | —            | —             |
| Ebert et al<sup>10</sup> (2011) | —            | —             | 41.5 ± 1.7   | 49.8 ± 1.8    | 37.1 ± 1.7   | 47.0 ± 1.8    |
| Ebert et al<sup>13</sup> (2010) | —            | —             | (n = 34)     | (n = 34)      | (n = 36)     | (n = 36)      |
| Ebert et al<sup>10</sup> (2012) | —            | —             | (n = 31)     | (n = 31)      | (n = 32)     | (n = 32)      |
| Total                        | 35.1 ± 1.9   | 49.1 ± 2.5    | 41.1 ± 2.5   | 49.6 ± 2.0    | 37.1 ± 2.5   | 47.3 ± 1.9    |
| Mean improvement             | 14.0         | 8.5           | 14.0         | 8.5           | 10.2         | 10.2          |
| Mean follow-up, y            | 2.0          | 3.1           | 2.0          | 3.1           | 3.6          | 3.6           |

| Study                        | Preoperative | Postoperative | Preoperative | Postoperative | Preoperative | Postoperative |
|------------------------------|--------------|---------------|--------------|---------------|--------------|---------------|
| SF-36 MCS                    |              |               |              |               |              |               |
| Ebert et al<sup>10</sup> (2017) | 51.1 ± 2.4   | 54.9 ± 1.7    | 51.5 ± 2.6   | 58.0 ± 1.9    | —            | —             |
| Ebert et al<sup>13</sup> (2013) | (n = 18)     | (n = 18)      | (n = 19)     | (n = 19)      | —            | —             |
| Ebert et al<sup>10</sup> (2011) | —            | —             | 51.2 ± 1.8   | 56.0 ± 1.1    | 52.3 ± 1.8   | 56.1 ± 1.1    |
| Ebert et al<sup>13</sup> (2010) | —            | —             | (n = 34)     | (n = 34)      | (n = 36)     | (n = 36)      |
| Ebert et al<sup>10</sup> (2012) | —            | —             | (n = 31)     | (n = 31)      | (n = 32)     | (n = 32)      |
| Total                        | 51.1 ± 2.4   | 54.9 ± 1.7    | 51.3 ± 2.5   | 56.2 ± 1.7    | 52.3 ± 2.5   | 55.1 ± 1.7    |
| Mean improvement             | 3.8          | 4.9           | 3.8          | 4.9           | 2.8          | 2.8           |
| Mean follow-up, y            | 2.0          | 3.1           | 2.0          | 3.1           | 3.6          | 3.6           |

<sup>a</sup>Scores are reported as mean ± SD and are taken from the latest postoperative evaluation for each nonoverlapping group of patients, with “total” reported as weighted mean ± composite SD. Significant improvements were found for each outcome in each group (P < 0.0001). MCS, mental component summary; PCS, physical component summary; SF-36, Short Form Health Survey–36; VAS, visual analog scale.

(P = .022), with a normalization of scores by 1-year follow-up. Otherwise, no significant difference in improvement or regression was found between groups.

SF-36 and VAS

SF-36 and VAS scores are presented in Table 6. Significant improvement was noted from preoperatively to latest follow-up within each group for each of these outcomes (P < .0001).

Knee Injury and Osteoarthritis Outcome Score

KOOS subscores are presented in Table 7. Significant improvement was noted from preoperatively to latest follow-up within each group for each of these subscales (P < .001).
| Study | Preoperative | Postoperative | Preoperative | Postoperative | Preoperative | Postoperative |
|-------|--------------|---------------|--------------|---------------|--------------|---------------|
| **KOOS SR** | | | | | | |
| Ebert et al\(^9\) (2011) | — | — | 29.4 ± 4.7 | 71.9 ± 4.7 | — | — |
| Ebert et al\(^12\) (2013) | (n = 18) | (n = 19) | (n = 34) | (n = 31) | (n = 36) | (n = 32) |
| Wondrasch et al\(^35\) (2015) | NR | 75.7 ± 19.3 | — | — | NR | 71.5 ± 24.7 |
| Total | 26.8 ± 5.8 | 70.5 ± 17.9 | 30.9 ± 5.8 | 67.0 ± 7.6 | 22.8 ± 4.7 | 62.1 ± 15.6 |
| Mean improvement | 43.7 | 36.1 | 39.3 | 31.8 | | |
| Mean follow-up, y | 2.9 | 3.1 | 3.6 | | | |
| **KOOS QOL** | | | | | | |
| Ebert et al\(^9\) (2011) | — | — | 37.0 ± 4.1 | 62.2 ± 4.5 | 29.7 ± 4.1 | 62.9 ± 4.4 |
| Ebert et al\(^12\) (2013) | (n = 18) | (n = 14) | (n = 34) | (n = 31) | (n = 36) | (n = 32) |
| Wondrasch et al\(^35\) (2015) | NR | 63.5 ± 16.0 | — | — | NR | 66.3 ± 21.2 |
| Total | 31.7 ± 3.7 | 64.7 ± 15.9 | 36.7 ± 4.1 | 62.3 ± 5.7 | 29.7 ± 4.1 | 61.7 ± 12.3 |
| Mean improvement | 33.0 | 25.6 | 32.0 | 31.8 | | |
| Mean follow-up, y | 2.9 | 3.1 | 3.6 | | | |
| **KOOS pain** | | | | | | |
| Ebert et al\(^9\) (2011) | — | — | 69.8 ± 3.2 | 85.5 ± 3.1 | 67.9 ± 3.2 | 86.0 ± 2.3 |
| Ebert et al\(^12\) (2013) | (n = 18) | (n = 14) | (n = 34) | (n = 31) | (n = 36) | (n = 32) |
| Wondrasch et al\(^35\) (2015) | NR | 82.7 ± 12.9 | — | — | NR | 84.5 ± 17.4 |
| Total | 63.2 ± 3.9 | 84.9 ± 11.2 | 69.1 ± 3.6 | 86.8 ± 3.6 | 67.9 ± 3.2 | 84.5 ± 8.6 |
| Mean improvement | 21.7 | 17.7 | 16.6 | 16.4 | | |
| Mean follow-up, y | 2.9 | 3.1 | 3.6 | | | |
| **KOOS symptoms** | | | | | | |
| Ebert et al\(^9\) (2011) | — | — | 74.5 ± 3.2 | 86.4 ± 3.1 | 68.6 ± 3.2 | 83.5 ± 4.2 |
| Ebert et al\(^12\) (2013) | (n = 18) | (n = 14) | (n = 34) | (n = 31) | (n = 36) | (n = 32) |
| Wondrasch et al\(^35\) (2015) | NR | 66.9 ± 4.5 | — | — | NR | 62.8 ± 9.8 |
| Total | 64.0 ± 4.3 | 73.4 ± 13.7 | 74.2 ± 3.6 | 87.6 ± 2.9 | 68.6 ± 3.2 | 76.3 ± 12.5 |

(continued)
TABLE 7 (continued)

| Study                  | Preoperative | Postoperative | Preoperative | Postoperative | Preoperative | Postoperative |
|------------------------|--------------|---------------|--------------|---------------|--------------|---------------|
| Mean improvement       | 9.4          | 13.4          | 7.7          |               |              |               |
| Mean follow-up, y      | 2.9          | 3.1           | 3.6          |               |              |               |
| KOOS ADL               |              |               |              |               |              |               |
| Ebert et al6 (2017)    | 73.8 ± 3.9   | 92.3 ± 2.8    | 80.6 ± 4.2   | 95.4 ± 3.0    | —            | —             |
| (n = 18)               |              |               | (n = 19)     |               | (n = 19)     |               |
| Ebert et al11 (2011)   | —            | —             | 81.9 ± 3.2   | 92.8 ± 2.4    | 76.9 ± 3.2   | 90.3 ± 2.4    |
| (n = 34)               |              |               | (n = 34)     |               | (n = 36)     |               |
| Ebert et al13 (2012)   | —            | —             | 81.9 ± 3.2   | 92.3 ± 2.2    | 76.9 ± 3.2   | 93.2 ± 1.8    |
| (n = 31)               |              |               | (n = 31)     |               | (n = 32)     |               |
| Wondrasch et al35 (2015)| NR           | 88.2 ± 10.6   | —            | —             | NR           | 87.7 ± 16.1   |
| (n = 14)               |              |               |              |               | (n = 15)     |               |
| Wondrasch et al36 (2009)| NR           | 86.3 ± 15.8   | —            | —             | NR           | 88.7 ± 12.6   |
| (n = 14)               |              |               |              |               | (n = 15)     |               |
| Total                  | 73.8 ± 3.9   | 89.2 ± 10.7   | 81.6 ± 3.4   | 93.2 ± 2.7    | 76.9 ± 3.2   | 90.6 ± 8.2    |
| (n = 18)               | (n = 46)     | (n = 84)      | (n = 84)     |               | (n = 68)     |               |
| Mean improvement       | 15.4         | 11.6          | 13.7         |               |              |               |
| Mean follow-up, y      | 2.9          | 3.1           | 3.6          |               |              |               |

*aSubscores are reported as mean ± SD, with “total” reported as weighted mean ± composite SD. Significant improvements were found for each outcome in each group (P < .001). ADL, activities of daily living; KOOS, Knee injury and Osteoarthritis Outcome Score; NR, not reported; QOL, quality of life; SR, sports and recreation.

**Tegner Activity Scale**

Two studies of overlapping patients35,36 identified no significant differences in the Tegner score between 6-week and 10/11-week groups at 2- or 5-year follow-up (time effect: \( P = .394 \); group effect: \( P = .204 \)). Both groups demonstrated improvement in the Tegner score from preoperative values, and a mean score of 4.0 was found for both groups at the 2- and 5-year follow-up periods.

**Functional Tests**

Functional test results are presented in Table 8. Significant improvement was noted from preoperatively to latest follow-up within each group for each of these tests (\( P < .0001 \)). No studies reported preoperative 6-minute walk test or range of motion results for the 6-week group, and therefore, mean improvement could not be calculated for this group.

**DISCUSSION**

Based on the results of this systematic review, patients undergoing MACI for articular cartilage lesions in the knee can be expected to experience improvement in clinical outcomes with the rehabilitation protocols outlined in this work. It should be noted that among the studies included that reported Tegner scores, a mean score of 4.0 was reported at follow-up, indicating that these were relatively low-activity patients.35,36 Although it could not be proven in this review that any of the rehabilitation groups improved to a significantly greater extent than the others, allowing patients to bear full weight at 6 weeks postoperatively allows a quicker return to activity and should be recommended given the significant improvement in various outcomes reported among this group.

Proper rehabilitation after MACI is essential to restore a patient's normal function without overloading the repair site. Several studies from the basic science literature have investigated the response of chondrocytes to mechanical stimuli.15,20,27,29 The effects of dynamic loading on chondrocyte differentiation and cellular synthesis depend both on the frequency and duration of cyclic loading.14 Elder et al15 found that cyclic loading of chick limb bud cells embedded in agarose gel resulted in a doubling of the number of cartilage nodules compared with nonloaded controls, while static compression was found to have little effect on cellular differentiation. In addition to cellular differentiation, Quinn et al27 found that dynamic compression of cartilage explants resulted in the stimulation of proteoglycan synthesis and pericellular deposition. Similarly, Sah et al29 found that higher frequency dynamic compression of cartilage explants resulted in greater glycosaminoglycan synthesis. Conversely, joint immobilization has been shown to have a deleterious effect on cartilage synthesis in animal models as a result of decreased proteoglycan synthesis and increased proteolysis.1,18,26 These findings stress the importance of early return to WB to stimulate cellular differentiation of the chondrocytes seeded into the collagen membranes used for MACI. However, returning to full WB too early after MACI may cause graft delamination or destruction.

Mechanical stimulation also has a beneficial effect on the integration of in vitro tissue-engineered implants with host tissue.33 This is particularly important for a procedure such as MACI, which relies on integration between a patient's
Clinically, CPM is frequently used immediately after articular cartilage procedures in the knee. Limited clinical evidence exists regarding the benefits of CPM on articular cartilage repair. However, in animal models, CPM has been shown to promote neochondrogenesis and to significantly improve knee motion and cartilage quality. All 7 studies from our review described using CPM early overloading the repair site before complete repair and integration of the graft. It is unclear how long it takes for these matrix scaffolds to heal and integrate with the surrounding native cartilage tissue, although this likely depends on a number of factors, including the type of scaffold, the defect size and location, the chondrocyte density of the scaffold, patient age, and the WB status of the patient.

The strengths of this study include a comprehensive systematic review performed by 2 independent reviewers. In addition, only randomized controlled trials (level 1 evidence) were included. The limitations of this study should also be noted. In particular, although 7 studies were included, these included only 3 nonoverlapping patient samples. In addition, the rehabilitation period comparisons were skewed such that one group (with 5 studies included in this review) primarily compared 8 versus 10 weeks to full WB, whereas another group (with 2 studies in this review) compared 6 versus 10 weeks to full WB. Furthermore, these 2 groups treated lesions of different sizes. Different MACI scaffolds and surgical procedures (either arthroscopic

### TABLE 8
Functional Test Results

| Study                  | 6 wk Preoperative | 6 wk Postoperative | 8 wk Preoperative | 8 wk Postoperative | 10/11 wk Preoperative | 10/11 wk Postoperative |
|------------------------|-------------------|--------------------|-------------------|--------------------|-----------------------|------------------------|
|                        | Preoperative      | Postoperative      | Preoperative      | Postoperative      | Preoperative          | Postoperative          |
|                        |                   |                    |                   |                    |                       |                        |
|                        | Mean improvement  |                    | Mean improvement  |                    | Mean improvement      |                        |
|                        | 656.0 ± 22.0      | NR                 | 664.0 ± 24.0      | NR                 | —                     | —                      |
|                        | (n = 18)          |                    | (n = 19)          |                    | (n = 36)              |                        |
|                        | Mean follow-up, y | 2.0                | 93.9              | 3.1                | 3.4                   |                        |
| Maximum knee flexion, deg |                   |                    |                   |                    |                       |                        |
|                        | Preoperative      | Postoperative      | Preoperative      | Postoperative      | Preoperative          | Postoperative          |
|                        | Mean improvement  |                    | Mean improvement  |                    | Mean improvement      |                        |
|                        | -1.8 ± 0.4        | NR                 | -2.0 ± 0.4        | NR                 | —                     | —                      |
|                        | (n = 18)          |                    | (n = 19)          |                    | (n = 36)              |                        |
|                        | Mean follow-up, y | 2.0                | 7.1               | 3.1                | 3.4                   |                        |

*Results are reported as mean ± SD, with “total” reported as weighted mean ± composite SD. Significant improvements were found for each outcome in the 8-week and 10/11-week groups (p < .0001). NR, not reported.*

healthy, native cartilage tissue and the chondrocyte-seeded collagen scaffold implanted into the defect site.
surgery or mini-arthroscopy for the second stage of the MACI procedure) were included and grouped together to create a sample size large enough for clinical outcome comparisons. The mean follow-up duration differed between groups, which may have an effect on some of the outcomes assessed. The studies did not provide demographic information on the patients who failed treatment, and therefore, it was not possible to conduct a subanalysis based on these factors. Most studies did not report on the mean time from initial injury until treatment with MACI. All lesions included in this review were on the medial or lateral femoral condyle, and therefore, the results of this review are not indicative of chondral lesions treated on the tibial plateaus or in the patellofemoral joint. Finally, although rehabilitation protocols of the respective 6-week, 8-week, and 10/11-week groups were reflective of time to return to full WB, they were not otherwise identical.

CONCLUSION

Based on the findings of this systematic review, patients undergoing MACI for articular cartilage lesions in the knee can be expected to experience improvement in clinical outcomes with the rehabilitation protocols outlined in this work.

REFERENCES

1. Behrens F, Kraft EL, Oegema TR Jr. Biochemical changes in articular cartilage after joint immobilization by casting or external fixation. J Orthop Res. 1989;7(3):335-343.
2. Bright P, Hambley K. A systematic review of reporting of rehabilitation in articular-cartilage-repair studies of third-generation autologous chondrocyte implantation in the knee. J Sport Rehabil. 2014;23(3):182-191.
3. Buckwalter JA. Articular cartilage injuries. Clin Orthop Relat Res. 2002;402:21-37.
4. Chubinskaya S, Haudenschild D, Gasser S, et al. Articular cartilage injury and potential remedies. J Orthop Trauma. 2015;29 (suppl 12):S47-S52.
5. Ciccott MC, Kraeutler MJ, Austin LS, et al. The prevalence of articular cartilage changes in the knee joint in patients undergoing arthroscopy for meniscal pathology. Arthroscopy. 2012;28(10):1437-1444.
6. Coleman BD, Khan HM, Matfessi N, et al. Studies of surgical outcome after patellar tendinopathy: clinical significance of methodological deficiencies and guidelines for future studies. Victorian Institute of Sport Tendon Study Group. Scand J Med Sci Sports. 2000;10(1):2-11.
7. Curi WW, Krome J, Gordon ES, Rushing J, Smith BP, Poehling GG. Cartilage injuries: a review of 31,516 knee arthroscopies. Arthroscopy. 1997;13(4):456-460.
8. Ebert JR, Edwards PK, Fallon M, Ackland TR, Janes GC, Wood DJ. Two-year outcomes of a randomized trial investigating a 6-week return to full weightbearing after matrix-induced autologous chondrocyte implantation. Am J Sports Med. 2017;45(4):838-848.
9. Ebert JR, Fallon M, Robertson W, et al. Radiological assessment of accelerated versus traditional approaches to postoperative rehabilitation following matrix-induced autologous chondrocyte implantation. Cartilage. 2011;2(1):60-72.
10. Ebert JR, Fallon M, Zheng MH, Wood DJ, Ackland TR. A randomized trial comparing accelerated and traditional approaches to postoperative weightbearing rehabilitation after matrix-induced autologous chondrocyte implantation: findings at 5 years. Am J Sports Med. 2012;40(7):1527-1537.
11. Ebert JR, Robertson WB, Lloyd DG, Zheng MH, Wood DJ, Ackland T. A prospective, randomized comparison of traditional and accelerated approaches to postoperative rehabilitation following autologous chondrocyte implantation: 2-year clinical outcomes. Cartilage. 2010; 1(3):180-187.
12. Edwards PK, Ackland T, Ebert JR. Accelerated weightbearing rehabilitation after matrix-induced autologous chondrocyte implantation in the tibiofemoral joint: early clinical and radiological outcomes. Am J Sports Med. 2013;41(10):2314-2324.
13. Edwards PK, Ackland T, Ebert JR. Clinical rehabilitation guidelines for matrix-induced autologous chondrocyte implantation on the tibiofemoral joint. J Orthop Sports Phys Ther. 2014;44(2):102-119.
14. Elder SH, Goldstein SA, Kimura JH, Soslowsky LJ, Spengler DM. Chondrocyte differentiation is modulated by frequency and duration of cyclic compressive loading. Ann Biomed Eng. 2001;29(6):476-482.
15. Elder SH, Kimura JH, Soslowsky LJ, Lavagnino M, Goldstein SA. Effect of compressive loading on chondrocyte differentiation in agarose cultures of chick limb-bud cells. J Orthop Res. 2000;18(1):78-86.
16. Enright PL. The six-minute walk test. Respir Care. 2003;48(8):783-785.
17. Fazalare JA, Griesser MJ, Siston RA, Flanagan DC. The use of continuous passive motion following knee cartilage defect surgery: a systematic review. Orthopedics. 2010;33(12):878.
18. Grumbles RM, Howell DS, Howard GA, et al. Cartilage metalloproteases in disuse atrophy. J Rheumatol Suppl. 1995;43:146-148.
19. Howard JS, Mattacola CG, Romine SE, Lattermann C. Continuous passive motion, early weight bearing, and active motion following knee articular cartilage repair: evidence for clinical practice. Cartilage. 2010;1(4):276-286.
20. Hunter CJ, Imler SM, Malaviya P, Nerem RM, Levenston ME. Mechanical compression alters gene expression and extracellular matrix synthesis by chondrocytes cultured in collagen I gels. Biomaterials. 2002;23(4):1249-1259.
21. Knapp DM, Harris JD, Pangrazzi G, et al. The basic science of continuous passive motion in promoting knee health: a systematic review of studies in a rabbit model. Arthroscopy. 2013;29(10): 1722-1731.
22. Kraeutler MJ, Bravman JT, McCarty EC. Bone–patellar tendon–bone autograft versus allograft in outcomes of anterior cruciate ligament reconstruction: a meta-analysis of 5182 patients. Am J Sports Med. 2013;41(10):2439-2448.
23. Lyman S, Nakamura N, Cole BJ, Ergelet G, Gomoll AH, Farr J 2nd. Cartilage-repair innovation at a standstill: methodologic and regulatory pathways to breaking free. J Bone Joint Surg Am. 2016;98(15):e63.
24. Marlovits S, Striessnig G, Resinger CT. Definition of pertinent parameters for the evaluation of articular cartilage repair tissue with high-resolution magnetic resonance imaging. Eur J Radiol. 2004;52(3):310-319.
25. Mundl R, Bedi A, Chow L, et al. Cartilage restoration of the knee: a systematic review and meta-analysis of level 1 studies. Am J Sports Med. 2016;44(7):1888-1895.
26. Nakajima M, Wakitani S, Harada Y, Tanigami A, Tomita N. In vivo mechanical condition plays an important role for appearance of cartilage tissue in ES cell transplanted joint. J Orthop Res. 2008;26(1):10-17.
27. Quinn TM, Grodzinsky AJ, Buschmann MD, Kim YJ, Hunziker EB. Mechanical compression alters proteoglycan deposition and matrix deformation around individual cells in cartilage explants. J Cell Sci. 1998;111(pt 5):573-583.
28. Rossa EM, Lohmander LS. The Knee Injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes. 2003;1:64.
29. Sah RL, Kim YJ, Doong JY, Grodzinsky AJ, Plaa AH, Sandy JD. Biosynthetic response of cartilage explants to dynamic compression. J Orthop Res. 1989;7(5):619-636.
30. Schrock JB, Kraeutler MJ, Hock DA, McQueen MB, McCarty EC. A cost-effectiveness analysis of surgical treatment modalities for
knee chondral lesions: microfracture, osteochondral autograft transplantation, and autologous chondrocyte implantation. Orthop J Sports Med. 2017;5(5):2325967117704634.

31. Schuette HB, Kraeutler MJ, McCarty EC. Matrix-assisted autologous chondrocyte transplantation in the knee: a systematic review of mid-to long-term clinical outcomes. Orthop J Sports Med. 2017;5(6):2325967117709250.

32. Tegner Y, Lysholm J. Rating systems in the evaluation of knee ligament injuries. Clin Orthop Relat Res. 1985;(198):43-49.

33. Theodoropoulos JS, DeCroos AJ, Peterra M, Park S, Kandel RA. Mechanical stimulation enhances integration in an in vitro model of cartilage repair. Knee Surg Sports Traumatol Arthrosc. 2016;24(6):2055-2064.

34. Ware JJ, Kosinski M, Keller SD. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-233.

35. Wondrasch B, Risberg M, Zak L, Marlovits S, Aldrian S. Effect of accelerated weightbearing after matrix-associated autologous chondrocyte implantation on the femoral condyle: a prospective, randomized controlled study presenting MRI-based and clinical outcomes after 5 years. Am J Sports Med. 2015;43(1):146-153.

36. Wondrasch B, Zak L, Weisch GH, Marlovits S. Effect of accelerated weightbearing after matrix-associated autologous chondrocyte implantation on the femoral condyle on radiographic and clinical outcome after 2 years: a prospective, randomized controlled pilot study. Am J Sports Med. 2009;37(suppl 1):S88-S96S.